REG - Ergomed plc - Exercise of options

ErgomedAnnouncement

21/06/2018 09:15

RNS Number : 1153S
Ergomed plc
21 June 2018
 


PRESS RELEASE
FOR IMMEDIATE RELEASE
 
 
Exercise of options
 
London, UK - 21 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that it has issued 47,000 new ordinary shares of 1p each in the Company ('New Ordinary Shares'). The New Ordinary Shares have been allotted pursuant to exercise of share options awarded to two individuals under the Ergomed plc Long Term Incentive Plan.
 
Application has been made to the London Stock Exchange for 47,000 Ordinary Shares to be admitted to trading on AIM ('Admission').  It is expected that Admission will occur at 8:00 a.m. on 22 June 2018. The Ordinary Shares will rank pari passu with the existing ordinary shares in the Company.
 
Following Admission, the Company's enlarged issued share capital and total number of voting rights will be 44,858,602 Ordinary Shares.
 
ENDS
 
Enquiries:
 




Ergomed plc


   Tel: +44 (0) 1483 503 205




Stephen Stamp (Chief Executive Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black (Joint Broker)


















N+1 Singer


Tel: +44 (0) 20 7496 3000




Aubrey Powel (Joint Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke













 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEFBMPTMBMTMPP